Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis
Recruiting · NCT06357741 · Observational (researchers observe without assigning treatment) · Lead sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.
Who can take part
Age range
45 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- patients with knee osteoarthritis whose inclusion criteria meet the "diagnostic criteria for arthritis" .
- no drug contraindications .
- aged between 45 and 75 .
- committed to follow the research procedures, And cooperate with the •implementation of the whole process study .
- the patient understands the relevant treatment process .
- the patient has the ability to give informed consent .
- The patient had not recently taken any medication that affected observation.
- the subjects must meet all the inclusion criteria to be eligible to participate in the study .
Exclusion criteria
- mental illness .
- patients with malignant tumors.
- patients with other infectious diseases .
- patients with metabolic bone disease, diabetes and hyperthyroidism.
- patients who cannot actively cooperate in the treatment.
- hypocalcemia.
Where it is running
1 location listed.
- Wuhan Union Hospital - Wuhan, Hubei, China